Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

CHAPTER 21

Translational PET Imaging Research in Psychiatry

The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late-phase clinical trials. Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs. CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy.

Publication details


Print publication date
02 Nov 2012
Copyright year
2012
Print ISBN
978-1-84973-365-6
PDF eISBN
978-1-84973-494-3
From the book series:
Drug Discovery